1Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, et al. (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084-3092.
2Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200.
3du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, et al. (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329.
4Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, et al. (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682-1691.
5Markman M (2008) Pharmaceutical management of ovarian cancer: current status. Drugs 68: 771-789.
6Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, et al. (2006) Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 16: 194-201.
7Hatok J, Babusikova E, Matakova T, Mistuna D, Dobrota D, et al. (2009) In vitro assays for the evaluation of drug resistance in tumor cells. Clin Exp Med 9: 1-7.
8. Hamburger AW (1981) Use of in vitro tests in predictive cancer chemotherapy. J Natl Cancer Inst 66: 981-988.
9Möllgard L, Prenkert M, Smolowicz A, Paul C, Tidefelt U (2003) In vitro chemosensitivity testing of selected myeloid cells in acute myeloid leukemia. Leuk Lymphoma 44: 783-789.
10Samson DJ, Seidenfeld J, Ziegler K, Aronson N (2004) Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22: 3618-3630.
11Nagourney RA (2006) Ex vivo programmed cell death and the prediction of response to chemotherapy. Curr Treat Options Oncol 7: 103-110.
12Schink JC, Copeland LJ (2011) Point: chemosensitivity assays have a role in the management of recurrent ovarian cancer. J Natl Compr Canc Netw 9: 115-120.
13Xu JM, Song ST, Tang ZM, Jiang ZF, Liu XQ, et al. (1999) Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat 53: 77-85.
14Mehta RS, Bornstein R, Yu IR, Parker RJ, McClaren CE, et al. (2001) Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Research and Treatment 66: 225-237.
15Fruehauf JP (2002) In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer 9: 171-182.
16Bosanquet AG (2007) Laboratory tests of cytotoxic drug sensitivity. Biomedical Scientist 51: 432-435.
17Orr JW Jr, Orr P, Kern DH (1999) Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J Sci Am 5: 174-178.
18Havrilesky LJ, Krivak TC, Mucenski JW, Myers ER (2010) Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. Am J Obstet Gynecol 203: 160-167.
19Kubota T, Weisenthal L (2006) Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question. Gastric Cancer 9: 82-87.
20Loum E, Giraud S, Bessette B, Battu S, Mathonnet M, et al. (2010) Oncogramme, a new individualized tumor response testing method: application to colon cancer. Cytotechnology 62: 381-388.
21Giraud S, Loum E, Bessette B, Fermeaux V, Lautrette C (2011) Oncogramme, a new promising method for individualized breast tumor response testing for cancer treatment. Anticancer Res 31: 139-145.
22Umezu T, Kajiyama H, Terauchi M, Shibata K, Ino K, et al. (2007) Establishment of a new cell line of endometrioid carcinoma of the ovary and its chemosensitivity. Hum Cell 20: 71-76.
23Arienti C, Tesei A, Verdecchia GM, Framarini M, Virzì S, et al. (2011) Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. J Transl Med 9: 94.
24Chaudhury A, Das S, Bunte RM, Chiu GN (2012) Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. Int J Nanomedicine 7: 739-751.
25Andreotti PK, Cree IA, Kurbacher CM, Hartmann DM, Linder D, et al. (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55: 5276-5282.
26Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang THM, Nephew KP (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320.
27Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP (2004) In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol 92: 160-166.
28Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, et al. (2005) Cancer cell adaptation to chemotherapy. BMC Cancer 5: 78.
29Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, et al. (2005) Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecol Oncol 98: 360-368.
30Andreotti PK, Cree IA, Kurbacher CM, Hartmann DM, Linder D, et al. (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55: 5276-5282.
31Ng TY, Ngan HY, Cheng DK, Wong LC (1999) The effect of amifostine on the in vitro cytotoxicity of chemotherapeutic agents in three epithelial ovarian carcinoma cell lines. Gynecol Oncol 75: 194-197.
32Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Lele SB, et al. (1998) Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol 70: 392-397.
33Scully R, Sobin LH (1999) Histological typing of ovarian tumors, volume 9. New York: Springer Berlin.
34Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, et al. (2003) Pathology and classification of ovarian tumors. Cancer 97: 2631-2642.
35Cree IA (2009) Chemosensitivity and chemoresistance testing in ovarian cancer. Curr Opin Obstet Gynecol 21: 39-43.
36Brigulová K, Cervinka M, Tošner J, Sedláková I (2010) Chemoresistance testing of human ovarian cancer cells and its in vitro model. Toxicol In Vitro 24: 2108-2115.
37Han SS1, Choi SH, Lee YK, Kim JW, Park NH, et al. (2008) Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer. Cancer Invest 26: 426-430.
38Ballard KS, Homesley HD, Hodson C, Presant CA, Rutledge J, et al. (2010) Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment. J Gynecol Oncol 21: 45-49.
39Kalloger SE, Köbel M, Leung S, Mehl E, Gao D, et al. (2011) Calculator for ovarian carcinoma subtype prediction. Mod Pathol 24: 512-521.
40Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M (2009) Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 59: 300-305.
41Ma Z, Zhang T, Wang R, Cheng Z, Xu H, et al. (2011) Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism. Int J Gynecol Cancer 21: 616-624.
42Ngô C, Chéreau C, Nicco C, Weill B, Chapron C, et al. (2009) Reactive Oxygen Species Controls Endometriosis Progression. Am J Pathol 175: 225-234.
43Doglioni C, Dei Tos AP, Laurino L, Iuzzolino P, Chiarelli C, et al. (1996) Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 20: 1037-1046.
44Barberis MC, Faleri M, Veronese S, Casadio C, Viale G (1997) Calretinin A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 41: 1757-1761.
45Dunfield LD, Shepherd TG, Nachtigal MW (2002) Primary culture and mRNA analysis of human ovarian cells. Biol Proced Online 4: 55-61.
46Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, et al. (2005) Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecologic Oncology 98: 360-368.
47Rabinovich A, Medina L, Piura B, Huleihel M (2010) Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw 21: 122-128.
48Zhang C, Marmé A, Wenger T, Gutwein P, Edler L, et al. (2006) Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int J Oncol 28: 551-558.
49Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, et al. (2012) Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 130: 29-39.
50Cai J, Tang H, Xu L, Wang X, Yang C, et al. (2012) Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis 33: 20-29.
51Quiros RM, Valianou M, Kwon Y, Brown KM, Godwin AK, et al. (2008) Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner. Gynecol Oncol 110: 99-109.
52Knight LA, Kurbacher CM, Glaysher S, Fernando A, Reichelt R, et al. (2009) Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumor chemosensitivity assay. BMC Cancer 9: 38.
53Reed JC (1999) Dysregulation of apoptosis in cancer. J Clin Oncol 17: 2941-2953.
54Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, et al. (2003) Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189: 1301-1307.
55Arienti C, Tesei A, Verdecchia GM, Framarini M, Virzì S, et al. (2011) Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. J Transl Med 9: 94.
56Herzog TJ, Krivak TC, Fader AN, Coleman RL (2010) Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol 203: 68.e1-6.
57Giraud S, Bounaix Morand du Puch CB, Fermeaux V, Guillaudeau A, et al. (2012) Oncogramme responses of breast tumour cells treated with herceptin correlate with HER2/C-ERB B2 pathological status. Anticancer Res 32: 1323-1325.
58Matsuo K, Bond VK, Eno ML, Im DD, Rosenshein NB (2009) Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int J Cancer 125: 2721-2727.
59Herzog TJ, Krivak TC, Fader AN, Coleman RL (2010) Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol 203: 68.e1-6.